The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...

HELSINKI — In patients with large vessel occlusion stroke treated within 4.5 hours of symptom onset, outcomes were better in those who received the thrombolytic tenecteplase prior to endovascular ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Three years ago, 10 Ascension Seton hospitals made a change in the type of medication they gave people experiencing an ischemic stroke. The outcomes of that switch have now been published in the ...

A newer type of "clot-busting" medication might be safer than the one long used for treating strokes, a preliminary study hints. Researchers found that among nearly 7,900 stroke sufferers, those ...

New research from the University of Texas Dell Medical School could help change the way strokes are treated. Dr. Steven Warach, a Dell Medical School neurology professor and director of the stroke ...